Loading stock data…
$58.13-2.60 (-4.28%)
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. in the Healthcare sector is trading at $58.13 with a market capitalization of $12.2B. Wall Street consensus targets $107.23 (13 analysts), implying a +84.5% move over the next 12 months. The stock is currently 39% below its 52-week high of $95.49, remaining 19.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 19 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $75.25M↑ | $73.74M↓ | $264.03M↑ | $256.47M↑ | $27.77M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$170.09M↓ | -$141.26M↓ | $40.81M↓ | $44.11M↑ | -$165.55M |
| Net Income | -$194.28M↓ | -$132.73M↓ | $30.81M↑ | -$23.75M↑ | -$175.24M |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of ang...